UNSPSC 51342305: Ganciclovir

This classification denotes a purine antagonist and antiviral agent with the molecular formula C9H13N5O4, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier P9G3CKZ4P5, chemically known as 9-(1,3-dihydroxy-propoxymethane)guanine but generally known as ganciclovir, which bears US NIH Compound Identifier 3454. European Medicines Agency schedules Ganciclovir in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB07881MIG.

UNSPSC 51342305 Ganciclovir, a Commodity code, shows minimal recent activity directly aligned with its nominal scope of a single antiviral pharmaceutical. State and local procurement bodies rarely solicit ganciclovir by name; the recent opportunities tagged under this code involve broader pharmaceutical purchasing programs—naloxone, medical supplies, and generic multi-source drugs—that do not focus on antiviral therapies. Issuing bodies pursuing pharmaceutical procurement at the state and local level include county health departments, city fire and rescue divisions, state health and human services agencies, and multistate cooperative purchasing alliances. When pharmaceutical procurement does occur in this tier, it typically flows through centralized state contracts, cooperative purchasing vehicles, or standing agreements with authorized wholesalers rather than direct commodity-level RFPs naming a single active pharmaceutical ingredient. The Tampa Fire Department's medical supplies bid and the Minnesota Multistate Cooperative Purchasing Alliance's generic pharmaceutical RFP illustrate the broader structure: state and local buyers use cooperative frameworks and authorized distributor relationships to source pharmaceuticals at volume, with pricing and compliance requirements managed through intermediaries rather than direct manufacturer or single-SKU solicitations.

Recent opportunities show activity concentrated in Florida, Minnesota, and Texas, with the most substantive pharmaceutical procurement through cooperative purchasing vehicles. Seminole County, Florida released IFB 60459723LAS in June 2026 for naloxone and drug deactivation systems with a July 26, 2026 response deadline; the City of Tampa issued IFB 26P00145 in March 2026 for medical and first aid supplies ($700,000 estimated value, sheltered for certified Small Local Business Enterprises) due March 13, 2026; and the Minnesota Department of Administration's MMCAP alliance released RFP S1070000015802 in January 2026 for generic multi-source pharmaceuticals and OTC products with a March 26, 2026 deadline. The Texas Health and Human Services Commission issued RFI HHS0017013 in April 2026 seeking vendor capabilities for direct-to-manufacturer prescription programs, signaling emerging state interest in alternative pharmacy supply models. No solicitations specifically name ganciclovir or other antiviral monotherapies, indicating that direct commodity procurement under this code remains inactive in the current state and local contracting environment.